Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis.

ABSTRACT:

Background

Brivaracetam is a novel third-generation antiseizure medication and an analog of levetiracetam with selective affinity for synaptic vesicle protein 2A (SV2A). By binding SV2A, brivaracetam decreases pre-synaptic neurotransmitter release.

Aim

We aimed to assess the safety and efficacy of brivaracetam in pediatric epilepsy.

Method

We searched PubMed, Scopus, and Web of Science (WOS) for relevant clinical and observational studies from inception until February 2024. We carried out statistical analysis using Open Meta-Analyst. Dichotomous data were pooled as proportions with a 95% confidence interval (CI).

Results

Eleven studies with a total of 805 patients were identified. The analysis of four studies revealed the more than 50% responder rate in a cohor

SUBMITTER: Hassan MA 

PROVIDER: S-EPMC12267362 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature